Latest Dividend Policy News

Sports Entertainment Group (SEG) reported a 62% jump in underlying EBITDA for FY25, underpinned by strong margin expansion and operational leverage. The company reaffirms its optimistic FY26 outlook with double-digit EBITDA growth expected.

ECP Emerging Growth Limited reported a modest 2.4% return for FY2025, lagging the ASX Small Ordinaries Index, but is pursuing new strategies including a pre-IPO fund investment and a special dividend to address shareholder value concerns.

Genesis Energy’s 2025 Investor Day confirms its strategy and earnings growth remain firmly on track, anchored by a substantial renewable pipeline and robust capital management.

Global Masters Fund Limited (GFL) reported a robust 19.8% total return for FY2025, surpassing the MSCI World Index, while unveiling strategic moves to diversify beyond Berkshire Hathaway into private growth and regional quality funds.

Solvar Limited has sold its New Zealand arrears loan book for NZ$8 million, accelerating its exit from the NZ market and announcing a special fully franked dividend for shareholders.

Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.

Wesfarmers has set the allocation price for shares issued under its Dividend Investment Plan for the special dividend at $81.0055, with just over 12% of shareholders opting in. Shares will be allocated on 4 December 2025.

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Ryman Healthcare has completed a full refinancing of its $2 billion syndicated loan facilities, extending the average maturity to five years and enhancing funding flexibility. The move aligns with the company’s disciplined growth strategy and sets the stage for future capital management decisions.

Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.

Oceania Healthcare Limited reported a robust 1HY26 performance, marked by increased sales volumes, improved care profitability, and disciplined capital management. The company’s strategic focus on sales, operational excellence, and debt reduction sets a solid foundation for sustainable growth.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.